We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Press Releases

Bioxodes’ antithrombotic meets development milestones – Company to launch Series A financing round to bring product to the clinic

Bioxodes’ antithrombotic meets development milestones – Company to launch Series A financing round to bring product to the clinic
Press Releases
Bioxodes’ antithrombotic meets development milestones – Company to launch Series A financing round to bring product to the clinic

Marche-en-Famenne, Belgium, 2015

Bioxodes SA, the Belgian-based start-up developing pharmaceutical products derived from natural sources, announces that it has successfully brought its lead product, Ir-CPI, trough pre-clinical development confirming its potential as the first in a new class of antithrombotic medicines. The company is now poised to initiate the studies required for clinical entry.